Anadys Aims To Resume Hep C Trials By Year End Pending Toxicology Data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Anadys Pharmaceuticals and partner Novartis plan to meet with FDA in the second half of the year to discuss the results of an ongoing preclinical toxicology study it hopes will lead FDA to lift a clinical hold on its oral hepatitis treatment ANA975, Anadys CEO Lawrence Fritz told Pharmaceutical Approvals Monthly Feb. 23